4824 results about "Bioavailability" patented technology

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of medicines, in particular to a GLP-1 agonist as well as a preparation method and application thereof. The GLP-1 agonist has a structure as shown in a formula I, or a pharmaceutically acceptable salt or solvate thereof. The GLP-1 agonist provided by the invention has relatively high activity and bioavailability.

The present invention belongs to the technical field of cosmetic raw materials, and specifically relates to a kind of oxidized hyaluronic acid-PDRN-peptide nanoemulsion and its preparation method. The nanoemulsion comprises oxidized hyaluronic acid, PDRN and polypeptide, and the nanoemulsion is formed by oxidized hyaluronic acid, PDRN and polypeptide through layer-by-layer self-assembly technology. Specifically: positively charged polypeptide is used to wrap negatively charged PDRN to form positively charged composite particles, or negatively charged PDRN is used to wrap positively charged polypeptide to form electrostatic composite particles, and then, the positively charged composite particles or the electrostatic composite particles are further wrapped with oxidized hyaluronic acid as a packaging material, and finally oxidized hyaluronic acid-PDRN-peptide nanoemulsion is formed. The nanoemulsion of the present invention can improve the stability of polypeptides, improve the problems that polypeptide molecules are difficult to penetrate the skin and have low bioavailability, and effectively improve the transdermal rate and stability of PDRN, give play to the tissue repair function of PDRN, further amplify the anti-inflammatory effects of the two, and improve the bioavailability of active ingredients.

Pharmaceutical compositions for the transmucosal delivery of N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with a monoamine oxidase inhibitor to achieve desired bioavailability suitable for the treatment of neurological disorders.

The invention provides a substituted tetrahydrofuran carboxamide derivative, salt or stereochemical isomer, a pharmaceutical composition containing the substituted tetrahydrofuran carboxamide derivative, application of the substituted tetrahydrofuran carboxamide derivative as a Nav inhibitor and application of the substituted tetrahydrofuran carboxamide derivative in preparation of drugs for treating and / or relieving pain and pain related diseases. The compound provided by the invention has the advantages of high metabolic stability, high oral absorption, better bioavailability, better activity, higher selectivity, better pharmacokinetic property, quicker effect, low side effect on central nervous system and the like.

The invention belongs to the field of biotechnology and medicine, and discloses mRNA (messenger Ribonucleic Acid) for coding luciferase and application thereof. The mRNA for coding the luciferase comprises an ORF sequence for coding the luciferase, and the ORF sequence for coding the luciferase is a nucleotide sequence as shown in one of SEQ ID NO: 10 to SEQ ID NO: 13. The invention provides a brand-new mRNA for coding luciferase, and the mRNA is stable in structure, not easy to degrade, high in translation efficiency, relatively high in protein yield, relatively high in biological availability and safety by reasonably optimizing a nucleic acid sequence of a functional region, can be applied as a reporter gene, and has good potential.

The invention relates to protein nanoparticles for treating ulcerative colitis as well as a preparation method and application thereof, and relates to the field of nano pharmaceutical preparations. 5-aminosalicylic acid is encapsulated in zein to achieve the purpose of improving the bioavailability of the 5-aminosalicylic acid by preparing protein nanoparticles of a targeted inflammation colon part, mannose grafted hyaluronic acid is used as a stabilizer to be attached to the surfaces of the zein nanoparticles through electrostatic adsorption and hydrogen-bond interaction, and the bioavailability of the 5-aminosalicylic acid is improved. Mannose can be targeted to immune cells through a mannose receptor, and can be cooperated with 5-aminosalicylic acid to treat ulcerative colitis. The hyaluronic acid has the effects of stabilizing the protein nanoparticles and targeting macrophages and intestinal epithelial cell CD44 receptors in ulcerative colitis tissues, so that aggregation of the nanoparticles in the colitis tissues is mediated, the protein nanoparticles have the functions of resisting inflammation, resisting oxidation and repairing barrier injury, and a new research direction is provided for treatment of ulcerative colitis.

The invention provides a compound DOTA-HX2-DZ and application thereof, and belongs to the technical field of biological medicine. According to the invention, the molecular structure of DZ-HX2-DOTA is optimized, and a special connexon is designed and adopted, so that the problem of limited anti-tumor curative effect caused by poorer stability, fat solubility, tumor residence time and other properties of a radiolabeled drug in the prior art is solved. The compound provided by the invention can significantly reduce the risk of label removal of radioactive metal ions in an in-vivo environment, and ensures that the compound stably plays a role at a targeted part; the compound has excellent molecular lipid solubility, can penetrate cell membranes and vascular barriers more easily, improves the bioavailability of drugs, prolongs the in-vivo circulation time, prolongs the tumor residence time, and further improves the treatment efficiency. The DZ-HX2-DOTA disclosed by the invention has broad-spectrum tumor targeting property, and can be used for diagnosing and treating various types of malignant tumors.

The invention relates to the technical field of cosmetics, in particular to an acne-removing composition, lipidosome and a preparation method and application thereof. The acne-removing composition disclosed by the invention is prepared from the following components in parts by weight: 2 to 8 parts of nicotinamide, 1 to 5 parts of cortex magnoliae officinalis extract, 0.15 to 2.01 parts of glycyrrhizic acid, 0.1 to 2 parts of totarol and 0.01 to 0.15 part of hyssopus officinalis extract. The nano-carrier is adopted to wrap and deliver the acne removal composition, so that the solubility of the functional components is increased, the bioavailability of the functional components is improved, meanwhile, the irritation of the functional components is also improved, multi-target co-delivery and multi-mechanism acne removal are realized, and the acne removal composition has a remarkable acne removal effect.

The invention relates to the technical field of pharmaceutical preparations, and discloses a composition with liver protection and antioxidation effects and a preparation method thereof.The composition is prepared from galactosamine modified astragalus membranaceus exosome, schisandra chinensis nanocrystals, liquorice-chitosan nanoparticles, lactobacillus acidophilus freeze-dried powder, beta-(1, 3) / (1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate) sourced from saccharomyces cerevisiae, and beta-(1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate). And (6) a dextran, grape exosome-curcumin hybrid vesicle freeze-dried powder, a curcumin-mitochondrial targeting peptide compound, a resveratrol-hydroxypropyl-beta-cyclodextrin inclusion compound and reduced panthenol. According to the liver-protecting and anti-oxidation composition disclosed by the invention, multi-dimensional intervention on liver protection is realized through an elaborately designed ternary system. The system is composed of a traditional Chinese medicine extract, a microorganism-plant exosome combination and a high-bioavailability antioxidant, all the parts have a synergistic effect, and the liver protection effect is remarkably improved.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The invention provides a stem cell exosome vesicle induced by traditional Chinese medicine functional components as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the stem cell exosome vesicle, traditional Chinese medicine functional components serve as an exosome inducer, stem cells can be induced to proliferate and secrete exosome with the enhanced function, the yield of the exosome can be increased, bioactive molecules can be loaded, and the bioavailability of the exosome in diabetes treatment is remarkably improved. The stem cell exosome vesicle disclosed by the invention can be applied to treatment of diabetes and complications thereof, not only can improve functions of islet cells, but also can treat chronic inflammation, microangiopathy and other metabolic diseases related to diabetes, and has a wide clinical application prospect.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses an amorphous solid form of a compound as shown in a formula (I), an X-ray powder diffraction pattern of the amorphous solid form has no characteristic diffraction peak within the 2 theta angle range of 0-40 degrees, the amorphous solid form as shown in the figure 1 has good stability, the dissolution rate of tablets prepared from the amorphous solid form can reach 95% or above within 10 min, and the dissolution rate of the tablets can reach 95% or above within 10 min. Meanwhile, excellent dissolution uniformity is achieved, high solubility can be achieved in the human physiological pH environment, and the oral bioavailability of the tigorazan is greatly improved. The preparation method of the amorphous solid comprises the following steps: adding the following formula (I) into an organic solvent, heating, dissolving, cooling, adding a poor solvent, and crystallizing to obtain the amorphous solid. The method is simple in step, easy to operate, capable of effectively reducing cost and suitable for industrial large-scale production. # imgabs0 #

The invention discloses a ginseng extract rich in rare saponins and preparation and anti-aging application thereof, and belongs to the technical field of oral beauty and skin care products, the ginseng extract is obtained by fermentation treatment of ginseng powder through phytobacterium plantarum, and the preservation number of the phytobacterium plantarum is GDMCC No.64374. The ginseng extract rich in rare saponin is fermented by specific plant lactobacillus, ginsenoside is efficiently converted into CK and F1, various natural plant components such as ginseng polysaccharide are reserved, and a specific synergistic effect is generated. Through verification, the prepared ginseng extract is high in bioavailability, can more effectively inhibit cell inflammation, and can more effectively recover the mitochondrial function of senescent cells and inhibit cell senescence. The preparation method provided by the invention is high in operability and easy to standardize and intellectualize. Compared with a traditional extraction and purification method, the adopted fermentation method is more environmentally friendly and efficient, and large-scale production can be achieved in industrial production.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a nasal gel for treating allergic rhinitis and a preparation method thereof, and relates to the technical field of medicines. The nasal gel for treating allergic rhinitis is prepared from double-sensitive double-network drug-loaded gel microspheres and a temperature-sensitive gel material, the double-sensitive double-network drug-loaded gel microspheres are prepared from sodium alginate, a temperature-sensitive polymer, lactoferrin, a traditional Chinese medicine extracting solution and calcium chloride, the temperature-sensitive gel material is prepared from silk fibroin, carboxymethyl chitosan, K-carrageenan and genipin; the double-sensitive double-network drug-loading gel microspheres are loaded in the temperature-sensitive gel material, and after the temperature-sensitive gel material enters the nasal cavity, the temperature-sensitive gel material is quickly converted into gel to be adhered to nasal cilia, so that the removal of the double-sensitive double-network drug-loading gel microspheres by the motion of the nasal cilia is reduced, and the gel microspheres can better release a double-layer drug-loading system; the acting time of the medicine in the nasal cavity is prolonged, the bioavailability of the medicine is improved, the allergic rhinitis is effectively treated, and uncomfortable symptoms are relieved.

The invention relates to curcumin-loaded pectin sodium alginate gel as well as a preparation method and application thereof, and belongs to the technical field of gel preparation. The preparation method of the curcumin-loaded pectin sodium alginate gel comprises the following steps: in a dark environment, stirring and mixing curcumin, arjunic acid, ortho-aminophenol and an organic solvent, adding a polyvinyl alcohol aqueous solution, a sodium alginate solution and a pectin solution, uniformly mixing, performing ultrasonic treatment, adding calcium chloride, stirring and mixing, performing ultrasonic treatment, and performing vacuum drying to obtain the curcumin-loaded pectin sodium alginate gel. And adding oxidized hyaluronic acid, continuously stirring, stirring at normal temperature until the organic solvent is completely volatilized, and cleaning the hydrogel with deionized water to obtain the hydrogel. According to the invention, calcium ions and sodium alginate are subjected to physical crosslinking, pectin and polyvinyl alcohol are combined to form a composite hydrogel layer, the compounding of multiple components can effectively control the dissolution and drug release behaviors of active components, the bioavailability of curcumin is increased, the compactness and stability of hydrogel are increased, and the bioavailability of curcumin is improved. The oxidation resistance of the hydrogel can be effectively improved.

The invention discloses an atorvaquone enteric-coated tablet, the preparation comprises atorvaquone, glyceryl behenate, teloxpol, a filler, an adhesive, a disintegrating agent and an enteric coating, and the particle size D90 of the atorvaquone is 30-50 [mu] m. The atorvaquone enteric-coated tablet disclosed by the invention is stable and continuous in release and high in bioavailability, can be positioned and released in intestinal tracts and reduce liver circulation, so that the occurrence of phenomena such as liver injury is reduced, the phenomena such as sticking and cracking are avoided in a tabletting process, the quality is qualified and stable, and the dissolution performance and the stability of the atorvaquone enteric-coated tablet are also ensured.

The invention relates to the technical fields of medicines, foods, daily chemicals and the like, in particular to two supramolecular eutectic crystals for better solving the application problem of EGCG (epigallocatechin gallate). The preparation method comprises the following steps: firstly, enabling EGCG and betaine to form a supramolecular EGCG betaine eutectic through a supramolecular technology, and synthesizing the supramolecular EGCG betaine eutectic through a supramolecular modification reaction by taking EGCG and betaine as precursors, so that the stability of EGCG can be improved to a certain extent, and meanwhile, the EGCG and the betaine are combined to play a synergistic effect; the supramolecular raw material is formed by enabling supramolecular EGCG betaine eutectic crystals and cyclodextrin to form a supramolecular raw material through host-guest self-assembly, and hydroxypropyl-beta-cyclodextrin and supramolecular EGCG betaine are subjected to host-guest self-assembly to obtain the supramolecular raw material, the supramolecular raw material prepared by the method can solve the stability problem of EGCG, the bioavailability of EGCG is improved, and the bioavailability of EGCG is improved. And meanwhile, the composition has good effects of resisting oxidation, whitening, resisting inflammation, controlling oil and the like, and has a good application prospect.

The invention discloses a preparation method and application of a lactoferrin-sodium alginate hydrogel system, and the preparation method of the lactoferrin-sodium alginate hydrogel system comprises the following steps: S1, preparing a lactoferrin subunit solution; s2, preparing a lactoferrin-active substance co-assembly; s3, purifying; s4, preparing a sodium alginate solution; and S5, preparing the lactoferrin-sodium alginate hydrogel loaded with the active substance. According to the method disclosed by the invention, small-molecule active substances are encapsulated on the basis that lactoferrin has a natural cage-shaped structure and a self-assembly characteristic, and lactoferrin is modified by utilizing good gel characteristic and gastrointestinal digestion resistance characteristic of sodium alginate, so that a lactoferrin-sodium alginate co-protected active substance hydrogel system is constructed; the constructed system shows obvious superiority in processing adaptability and bioaccessibility, and the problems of poor stability, low bioavailability and the like of natural small-molecule active substances in the food processing process are solved.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention provides a nanoparticle compound for inhibiting bone and soft tissue infection as well as a preparation method and application thereof, and belongs to the technical field of medical biological materials. The nanoparticle compound is a gentiopicroside, sericin, hyaluronic acid and endolysin liposome nanoparticle, and a gentiopicroside, sericin, hyaluronic acid and endolysin co-delivery nano drug delivery system targeting the S100A4 site is designed based on the target S100A4 closely related to bone infection through Ai molecular docking and nano drug delivery technologies. The nanoparticle compound provided by the invention has better stability and bioavailability, and can be used for improving and relieving inflammatory response and increasing wound healing effect.